arrow
S

Sergio Siragusa

Department of Health Promotion
H指数:33
被引数:4,060

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety of red blood cell transfusion despite serologic incompatibility in autoimmune hemolytic anemia: A real-world multicenter study

尽管存在血清学不相容性,自身免疫性溶血性贫血患者输注红细胞的 safety:一项真实世界多中心研究

2026-07-230
OA
Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma

利妥昔单抗治疗血液学相关自身免疫性疾病或非霍奇金淋巴瘤患者的感染发生率

2026-05-090
OAAI
Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study

新诊断前列腺癌患者中单克隆丙种球蛋白病的患病率:一项相关性视角的观察性研究

2025-11-270
OAAI
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study

在Nilotinib减量后的慢性期慢性髓性白血病中的无治疗缓解:DANTE研究的96周更新

2025-08-080
OAAI
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design

探讨真性红细胞增多症的血栓栓塞危险因素:从现有证据到PROSPERO研究设计

2025-07-180
OA
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)
2024-12-010
OAAI
Management and Outcomes of Pregnancy and Childbirth in Known and Unknown Hemophilia Carriers: 10 Years Retrospective Evaluation from Southern Italy

已知和未知血友病携带者妊娠与分娩的管理及结局:意大利南部10年回顾性评估

BLOOD
IF23.1
2024-11-050
PRE
Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience
2024-10-310
OAAI
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
2024-03-183
OAAI